Jefferies Group's MLTX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 500,000 shares of MoonLake Immunotherapeutics (MLTX) worth $6.59 M, representing 0.03% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in MLTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 475,000 shares. Largest reduction occurred in Q3 2023, reducing 93,789 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's MoonLake Immunotherapeutics (MLTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly MoonLake Immunotherapeutics (MLTX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +475,000 | Add 1900.00% | 500,000 | $13.18 |
| Q3 2025 | +19,811 | Add 381.79% | 25,000 | $7.17 |
| Q2 2025 | -4,811 | Reduce 48.11% | 5,189 | $47.20 |
| Q1 2025 | +3,750 | Add 60.00% | 10,000 | $39.07 |
| Q4 2024 | +6,250 | New Buy | 6,250 | $54.15 |
| Q2 2024 | -12,332 | Sold Out | 0 | $0.00 |
| Q1 2024 | +1,757 | Add 16.61% | 12,332 | $50.23 |
| Q4 2023 | +10,575 | New Buy | 10,575 | $60.39 |
| Q3 2023 | -93,789 | Sold Out | 0 | $0.00 |
| Q2 2023 | +24,076 | Add 34.54% | 93,789 | $51.00 |
| Q1 2023 | +2,059 | Add 3.04% | 69,713 | $21.39 |
| Q4 2022 | +67,654 | New Buy | 67,654 | $10.50 |
Jefferies Group's MoonLake Immunotherapeutics Investment FAQs
Jefferies Group first purchased MoonLake Immunotherapeutics (MLTX) in Q4 2022, acquiring 67,654 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held MoonLake Immunotherapeutics (MLTX) for 12 quarters since Q4 2022.
Jefferies Group's largest addition to MoonLake Immunotherapeutics (MLTX) was in Q4 2025, adding 500,000 shares worth $6.59 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 500,000 shares of MoonLake Immunotherapeutics (MLTX), valued at approximately $6.59 M.
As of the Q4 2025 filing, MoonLake Immunotherapeutics (MLTX) represents approximately 0.03% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in MoonLake Immunotherapeutics (MLTX) was 500,000 shares, as reported at the end of Q4 2025.